Retina

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

Rishi Singh, MD, provides an overview of the stages of diabetic retinopathy and diabetic macular edema (DR/DME) and the retinal findings associated with each stage as well as factors to consider when selecting therapy.

Carolyn Majcher, OD, FAAO, discusses when to refer patients with diabetic retinopathy and diabetic macular edema (DR/DME) to a retina specialist.

Roche announced that faricimab met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept.

The approval of aflibercept for preterm infants with retinopathy of prematurity (ROP) expands the treatment armamentarium for these patients, comments Prof Anat Loewenstein.

According to Regeneron, aflibercept injection is now approved to treat five retinal conditions caused by ocular angiogenesis.

According to the company, EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function.

According to investigators, a new proposed classification for large and extra-large full-thickness macular holes is based on the surgical results achieved with different surgical techniques

Physician discusses existing advancements, innovations for treatment.

Carolyn Majcher, OD, FAAO, describes challenges primary eye care providers can experience when diagnosing diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss the standard diagnostic imaging tools that are available to detect diabetic retinopathy and diabetic macular edema (DR/DME).

Specialists seek more information for use in the treatment of patients diagnosed with retinal diseases

HG004 aims to be more effective than other AAV2 products in treatment of inherited retinal diseases caused by mutations in the RPE65 gene.

The workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.

Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.

Carolyn Majcher, OD, FAAO, provides an overview of the symptoms of diabetic retinopathy and diabetic macular edema (DR/DME) and recommendations for dilated eye exams for patients with type 1 and type 2 diabetes.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss the current prevalence and future projections of diabetic retinopathy and diabetic macular edema (DR/DME) as well as the impact of early diagnosis and treatment for patients with diabetic retinal diseases.

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

According to the company, it is planning to hold an end-of-phase 2 meeting with the FDA to discuss the results.

A team of researchers have found that STOC tomography enables unprecedented views of eye structure.

Researchers used obesity as a model to accelerate and exaggerate the stressors experienced by the body throughout life.

The study advances the understanding of the leading cause of visual impairment in adults.

Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.

Investigators found that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.

In a conversation with David Hutton of Ophthalmology Times®, Ferhina S. Ali, MD, MPH, discussed the real world use of faricimab in the IRIS Registry during a presentation this week at Hawaiian Eye in Kauai Hawaii, focusing on the use of faricimab for the treatment of neovascular AMD and diabetic macular edema.

According to researchers, factors that were associated with all type of visual impairment included older age, lower education level, and lower income were associated with all types of visual impairment.

Diabetic retinopathy is the leading cause of blindness in American adults, and a team of researchers believes the source of this damage may lie in the belly — mainly a leaky small intestine. A novel treatment can possibly prevent or reverse this damage.

Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report.

The researchers conducted a retrospective chart review of patients with typical exudative AMD that had been treated with anti-VEGF therapy injections.